TREATMENT OF STROKE USING ISOLATED PLACENTAL CELLS
First Claim
Patent Images
1. A method of treating an individual having a disruption in the flow of blood in or around the brain, comprising administering to said individual an effective amount of isolated human adherent placental cells that are:
- CD10+,CD34−
, and CD105+;
CD200+ and HLA-G+;
CD73+, CD105+, and CD200+;
CD200+ and OCT-4+;
CD73+, CD105+ and HLA-G+;
CD73+ and CD105+ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body;
orOCT-4+ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies;
or any combination thereof.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
210 Citations
61 Claims
-
1. A method of treating an individual having a disruption in the flow of blood in or around the brain, comprising administering to said individual an effective amount of isolated human adherent placental cells that are:
-
CD10+,CD34−
, and CD105+;CD200+ and HLA-G+; CD73+, CD105+, and CD200+; CD200+ and OCT-4+; CD73+, CD105+ and HLA-G+; CD73+ and CD105+ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body;
orOCT-4+ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies;
or any combination thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)
-
-
20. A method of treating an individual having a disruption in the flow of blood in or around the brain, comprising administering to said individual an effective amount of isolated human adherent placental cells, wherein said cells express one or more genes at a detectably higher level than a bone marrow-derived mesenchymal stem cell,
wherein said one or more genes are one or more of ACTG2, ADARB1, AMIGO2, ARTS-1, B4GALT6, BCHE, C11orf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, IL1A, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A, and wherein said bone marrow-derived stem cell has undergone a number of passages in culture that is equivalent to the number of passages said placental stem cell has undergone.
Specification